PharmaEngine Past Earnings Performance
Past criteria checks 2/6
PharmaEngine has been growing earnings at an average annual rate of 16.4%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 15.3% per year. PharmaEngine's return on equity is 7.1%, and it has net margins of 35.8%.
Key information
16.4%
Earnings growth rate
16.7%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 15.3% |
| Return on equity | 7.1% |
| Net Margin | 35.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?
Mar 30
How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 18Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?
Jan 14
We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability
Dec 10Revenue & Expenses BreakdownBeta
How PharmaEngine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 768 | 275 | 132 | 310 |
| 30 Sep 23 | 739 | 291 | 136 | 291 |
| 30 Jun 23 | 648 | 298 | 146 | 247 |
| 31 Mar 23 | 649 | 303 | 146 | 203 |
| 31 Dec 22 | 654 | 319 | 140 | 182 |
| 30 Sep 22 | 700 | 377 | 135 | 151 |
| 30 Jun 22 | 722 | 362 | 124 | 108 |
| 31 Mar 22 | 713 | 447 | 119 | 110 |
| 31 Dec 21 | 655 | 426 | 118 | 137 |
| 30 Sep 21 | 1,237 | 837 | 133 | 136 |
| 30 Jun 21 | 1,156 | 782 | 128 | 119 |
| 31 Mar 21 | 1,088 | 631 | 119 | 118 |
| 31 Dec 20 | 1,056 | 604 | 113 | 96 |
| 30 Sep 20 | 344 | 45 | 95 | 98 |
| 30 Jun 20 | 330 | 50 | 99 | 109 |
| 31 Mar 20 | 320 | 64 | 115 | 119 |
| 31 Dec 19 | 314 | 43 | 119 | 131 |
| 30 Sep 19 | 317 | 114 | 117 | 132 |
| 30 Jun 19 | 375 | 164 | 119 | 136 |
| 31 Mar 19 | 338 | 206 | 112 | 126 |
| 31 Dec 18 | 293 | 129 | 113 | 125 |
| 30 Sep 18 | 1,000 | 647 | 137 | 142 |
| 30 Jun 18 | 890 | 569 | 123 | 124 |
| 31 Mar 18 | 877 | 463 | 121 | 129 |
| 31 Dec 17 | 854 | 387 | 116 | 122 |
| 30 Sep 17 | 875 | 452 | 122 | 142 |
| 30 Jun 17 | 849 | 364 | 143 | 169 |
| 31 Mar 17 | 1,144 | 607 | 137 | 201 |
| 31 Dec 16 | 1,135 | 690 | 130 | 195 |
| 30 Sep 16 | 330 | 42 | 89 | 156 |
| 30 Jun 16 | 330 | 168 | 61 | 143 |
| 31 Mar 16 | 502 | 383 | 62 | 113 |
| 31 Dec 15 | 507 | 394 | 58 | 115 |
| 30 Sep 15 | 511 | 393 | 51 | 141 |
| 30 Jun 15 | 724 | 552 | 53 | 134 |
| 31 Mar 15 | 231 | 100 | 40 | 122 |
| 31 Dec 14 | 229 | 124 | 37 | 115 |
| 30 Sep 14 | 234 | 135 | 43 | 75 |
| 30 Jun 14 | 28 | -128 | 64 | 95 |
| 31 Mar 14 | 34 | -116 | 62 | 93 |
| 31 Dec 13 | 37 | -118 | 63 | 94 |
| 30 Sep 13 | 37 | -110 | 62 | 84 |
| 30 Jun 13 | 36 | -106 | 46 | 91 |
Quality Earnings: 4162 has high quality earnings.
Growing Profit Margin: 4162's current net profit margins (35.8%) are lower than last year (48.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4162's earnings have grown by 16.4% per year over the past 5 years.
Accelerating Growth: 4162's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4162 had negative earnings growth (-13.8%) over the past year, making it difficult to compare to the Biotechs industry average (-6.1%).
Return on Equity
High ROE: 4162's Return on Equity (7.1%) is considered low.